Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Shan Wu

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Bioorganic & Medicinal Chemistry Letters|June 1, 2016
Synthesis, crystal structures, molecular docking, and in vitro biological activities of transition metals with 4-(2,3-dichlorophenyl)piperazine-1-carboxylic acidDan-Dan Yang, Ya-Nan Chen, Yu-Shan Wu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 14, 2026
Lirafugratinib attenuates ABCG2-dependent drug efflux and restores chemosensitivity in multidrug-resistant nonsmall cell lung cancer cellsChung-Pu Wu, Yen-Ching Li, Bing-Huan Lin, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 7, 2022
The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugsChung-Pu Wu, Megumi Murakami, Yu-Shan Wu, et al.
Cancer Letters|September 13, 2017
Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell linesChung-Pu Wu, Sung-Han Hsiao, Megumi Murakami, et al.
International Journal of Molecular Sciences|November 11, 2022
Hydroxygenkwanin Improves the Efficacy of Cytotoxic Drugs in ABCG2-Overexpressing Multidrug-Resistant Cancer CellsYan-Qing Li, Megumi Murakami, Yang-Hui Huang, et al.
Pharmaceuticals (Basel, Switzerland)|November 25, 2023
Imperatorin Restores Chemosensitivity of Multidrug-Resistant Cancer Cells by Antagonizing ABCG2-Mediated Drug TransportChung-Pu Wu, Megumi Murakami, Yen-Ching Li, et al.
Frontiers in Cell and Developmental Biology|August 5, 2021
Branebrutinib (BMS-986195), a Bruton's Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic AgentsChung-Pu Wu, Megumi Murakami, Yu-Shan Wu, et al.
European Journal of Pharmacology|December 26, 2024
Vodobatinib overcomes cancer multidrug resistance by attenuating the drug efflux function of ABCB1 and ABCG2Yen-Ching Li, Bing-Huan Lin, Megumi Murakami, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 15, 2024
The colony-stimulating factor-1 receptor inhibitor edicotinib counteracts multidrug resistance in cancer cells by inhibiting ABCG2-mediated drug effluxYen-Ching Li, Yun-Chieh Lee, Megumi Murakami, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 10, 2024
Epertinib counteracts multidrug resistance in cancer cells by antagonizing the drug efflux function of ABCB1 and ABCG2Bing-Huan Lin, Yen-Ching Li, Megumi Murakami, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Bioorganic & Medicinal Chemistry Letters|June 1, 2016
Synthesis, crystal structures, molecular docking, and in vitro biological activities of transition metals with 4-(2,3-dichlorophenyl)piperazine-1-carboxylic acidDan-Dan Yang, Ya-Nan Chen, Yu-Shan Wu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 14, 2026
Lirafugratinib attenuates ABCG2-dependent drug efflux and restores chemosensitivity in multidrug-resistant nonsmall cell lung cancer cellsChung-Pu Wu, Yen-Ching Li, Bing-Huan Lin, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 7, 2022
The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugsChung-Pu Wu, Megumi Murakami, Yu-Shan Wu, et al.
Cancer Letters|September 13, 2017
Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell linesChung-Pu Wu, Sung-Han Hsiao, Megumi Murakami, et al.
International Journal of Molecular Sciences|November 11, 2022
Hydroxygenkwanin Improves the Efficacy of Cytotoxic Drugs in ABCG2-Overexpressing Multidrug-Resistant Cancer CellsYan-Qing Li, Megumi Murakami, Yang-Hui Huang, et al.
Pharmaceuticals (Basel, Switzerland)|November 25, 2023
Imperatorin Restores Chemosensitivity of Multidrug-Resistant Cancer Cells by Antagonizing ABCG2-Mediated Drug TransportChung-Pu Wu, Megumi Murakami, Yen-Ching Li, et al.
Frontiers in Cell and Developmental Biology|August 5, 2021
Branebrutinib (BMS-986195), a Bruton's Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic AgentsChung-Pu Wu, Megumi Murakami, Yu-Shan Wu, et al.
European Journal of Pharmacology|December 26, 2024
Vodobatinib overcomes cancer multidrug resistance by attenuating the drug efflux function of ABCB1 and ABCG2Yen-Ching Li, Bing-Huan Lin, Megumi Murakami, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 15, 2024
The colony-stimulating factor-1 receptor inhibitor edicotinib counteracts multidrug resistance in cancer cells by inhibiting ABCG2-mediated drug effluxYen-Ching Li, Yun-Chieh Lee, Megumi Murakami, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 10, 2024
Epertinib counteracts multidrug resistance in cancer cells by antagonizing the drug efflux function of ABCB1 and ABCG2Bing-Huan Lin, Yen-Ching Li, Megumi Murakami, et al.
Pageof 6